The Securities and Exchange Commission has not necessarily
reviewed the information in this filing and has not determined
if it is accurate and complete.
| |||||||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| ADC Therapeutics SA | COM | H0036K147 | 1,830,435 | 682,998 | SH | SOLE | None | 682,998 | 0 | 0 | |
| Babcock & Wilcox Enterprises Inc. | COM | 05614L209 | 2,324,626 | 2,416,200 | SH | SOLE | None | 2,416,200 | 0 | 0 | |
| Cibus, Inc. | COM | 17166A101 | 1,578,650 | 1,143,949 | SH | SOLE | None | 1,143,949 | 0 | 0 | |